MACH; Bernard

Patent Applications and Registrations

Patent applications and USPTO patent grants for MACH; Bernard.The latest application filed is for "anti-cd3 antibodies and methods of use thereof".

Company Profile

2.7.17

MACH; Bernard - Chambesy CH
Mach; Bernard - Pregny-Chambesy CH
Mach, Bernard - Chambesy-Geneve CH
Mach; Bernard - Geneva CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-cd3 Antibodies And Methods Of Use Thereof App 20210009691 - MACH; Bernard ; et al.	2021-01-14
Anti-CD3 antibodies and methods of use thereof Grant 10,759,858 - Mach , et al. Sep	2020-09-01
Anti-cd3 Antibodies And Methods Of Use Thereof App 20180194842 - MACH; Bernard ; et al.	2018-07-12
Anti-CD3 antibodies and methods of use thereof Grant 9,850,304 - Mach , et al. December 26, 2	2017-12-26
Anti-CD3 Antibodies And Methods Of Use Thereof App 20140193399 - Mach; Bernard ; et al.	2014-07-10
Anti-CD3 antibodies and methods of use thereof Grant 8,551,478 - Mach , et al. October 8, 2	2013-10-08
Anti-CD3 Antibodies and Methods of Use Thereof App 20100183554 - Mach; Bernard ; et al.	2010-07-22
Anti-CD3 antibodies and methods of use thereof Grant 7,728,114 - Mach , et al. June 1, 2	2010-06-01
Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances App 20090023152 - Masternak; Krysztof ; et al.	2009-01-22
Cannabinoid Compositions and Methods of Use Thereof App 20080262079 - Mach; Bernard ; et al.	2008-10-23
Multiple Sclerosis-related superantigen App 20070249808 - Conrad; Bernard ; et al.	2007-10-25
Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substanaces App 20070203327 - Masternak; Krysztof ; et al.	2007-08-30
Anti-CD3 antibodies and methods of use thereof App 20060177896 - Mach; Bernard ; et al.	2006-08-10
Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances App 20060024683 - Masternak; Krysztof ; et al.	2006-02-02
Methods of treating autoimmune and inflammatory diseases App 20050265993 - Mach, Bernard ; et al.	2005-12-01
Assays for the identification of modulators of MHC class II expression App 20050260661 - Mach, Bernard ; et al.	2005-11-24
Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens App 20050112556 - Conrad, Bernard ; et al.	2005-05-26
Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigens Grant 6,800,469 - Conrad , et al. October 5, 2	2004-10-05
Multiple sclerosis-related superantigen App 20040054133 - Conrad, Bernard ; et al.	2004-03-18
Allelic variants of HERV-K18, method for analysis thereof and use in the determination of genetic predisposition for disorders involving the HERV-K18 provirus App 20040009468 - Mach, Bernard ; et al.	2004-01-15
Nucleic acid sequences of CIITA genes which can be involved in controlling and regulating the expression of genes encoding MHC type II molecules, and their use, in particular as drugs Grant 6,632,604 - Mach October 14, 2	2003-10-14
Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances App 20020156258 - Masternak, Krzysztof ; et al.	2002-10-24
Nucleic Acid Sequences Of Ciita Genes Which Can Be Involved In Controlling And Regulating The Expression Of Genes Encoding Mhc Type Ii Molecules, And Their Use, In Particular As Drugs. App 20020151691 - MACH, BERNARD	2002-10-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.